Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma-Reference-Cited by-同舟云学术

Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma

Published:2024-06-26 Issue:13 Volume:67 Page:10548-10566
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Weiss Matthew M.¹^ORCID,Zheng Xiaozhang¹,Ji Nan¹,Browne Chris M.¹,Campbell Veronica¹,Chen Dapeng¹,Enerson Brad¹,Fei Xue¹,Huang Xin¹,Klaus Christine R.¹,Li Haoran¹,Mayo Michele¹,McDonald Alice A.¹,Paul Atanu¹,Rong Haojing¹,Sharma Kirti¹,Shi Yatao¹,Slavin Anthony¹,Walther Dirk M.¹,Yuan Karen¹,Zhang Yi¹,Zhu Xiao¹,Kelleher Joe¹,Walker Duncan¹,Mainolfi Nello¹

Affiliation:

1. Kymera Therapeutics, 200 Arsenal Yards Boulevardd, Watertown, Massachusetts 02472, United States

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01823

Reference29 articles.

1. SEER*Stat Software; Surveillance Research Program, National Cancer Institute, 2024; https://seer.cancer.gov/seerstat/.

2. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

3. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study

4. Toll-like Receptors are Key Participants in Innate Immune Responses

5. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases;Journal of Medicinal Chemistry;2024-08-16